Cited by 12Blood Pressure and Hypertension StudiesCardiovascular Health and Disease PreventionSodium Intake and Health

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Remnant cholesterol and intensive blood pressure control in older patients with hypertension: a post hoc analysis of the STEP randomized trial

Yang, Ruixue, Zhang, Juyan, Yu, Xiaoxu, Yang, Guohong, Cai, Jun·2024·European Journal of Preventive Cardiology

Abstract

Aims: Emerging evidence shows a close relationship between remnant cholesterol (RC) and hypertension. However, it is unknown whether RC is associated with the effects of intensive systolic blood pressure (SBP) lowering on cardiovascular outcomes. Methods and results: We performed a post hoc analysis of the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial. Participants were randomly allocated to intensive (110 to <130 mmHg) or standard (130 to <150 mmHg) treatment groups. The effects of intensive SBP lowering on the primary composite outcome (stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fibrillation, or cardiovascular death), the components thereof, and all-cause mortality were analysed by the tertile of baseline RC (lowest, middle, and highest). We followed 8206 patients for 3.33 years (median). The adjusted hazard ratios (HRs) [95% confidence interval (CI)] for the primary outcome were 1.06 (0.73–1.56), 0.58 (0.38–0.87), and 0.67 (0.46–0.96) in the lowest, middle, and highest RC tertiles, respectively (P for interaction = 0.11). However, significant heterogeneity in the treatment effects was observed when comparing the upper two tertiles with the lowest tertile (P for interaction = 0.033). For all-cause mortality, the adjusted HRs (95% CI) were 2.48 (1.30–4.73), 1.37 (0.71–2.65), and 0.42 (0.22–0.80) in the lowest, middle, and highest RC tertiles, respectively (P for interaction <0.0001). Conclusion: Baseline RC concentrations were associated with the effects of intensive SBP lowering on the primary composite cardiovascular outcome and all-cause mortality in hypertensive patients. These results are hypothesis-generating and merit further study. Registration: STEP ClinicalTrials.gov number: NCT03015311

Overview

Integrity signals

Registry

Crossref · 10.1093/eurjpc/zwae001

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 0 references

Research works printed but not linked: 37

  1. Bruemmer, 2021, Remnant cholesterol: the leftovers and their contribution to atherosclerotic cardiovascular disease, Circ Cardiovasc Imaging, 14, e012615, 10.1161/CIRCIMAGING.121.012615 · DOI
  2. Pirillo, 2020, Beyond LDL-C levels, does remnant cholesterol estimation matter?, Eur J Prev Cardiol, 27, 1088, 10.1177/2047487319899622 · DOI
  3. Jørgensen, 2013, Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction, Eur Heart J, 34, 1826, 10.1093/eurheartj/ehs431 · DOI · Paper page
  4. Kaltoft, 2020, Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study, Eur Heart J, 41, 2288, 10.1093/eurheartj/ehaa172 · DOI · Paper page
  5. Varbo, 2013, Remnant cholesterol as a causal risk factor for ischemic heart disease, J Am Coll Cardiol, 61, 427, 10.1016/j.jacc.2012.08.1026 · DOI · Paper page
  6. Gao, 2022, Remnant cholesterol predicts risk of cardiovascular events in patients with myocardial infarction with nonobstructive coronary arteries, J Am Heart Assoc, 11, e024366, 10.1161/JAHA.121.024366 · DOI
  7. Vallejo-Vaz, 2018, Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial, Circulation, 138, 770, 10.1161/CIRCULATIONAHA.117.032318 · DOI · Paper page
  8. Li, 2022, Remnant cholesterol variability and incident ischemic stroke in the general population, Stroke, 53, 1934, 10.1161/STROKEAHA.121.037756 · DOI
  9. Quispe, 2021, Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study, Eur Heart J, 42, 4324, 10.1093/eurheartj/ehab432 · DOI · Paper page
  10. Wang, 2022, Association between remnant cholesterol and arterial stiffness: a secondary analysis based on a cross-sectional study, J Clin Hypertens, 24, 26, 10.1111/jch.14384 · DOI
  11. Li, 2021, Associations between remnant lipoprotein cholesterol and central systolic blood pressure in a Chinese community-based population: a cross-sectional study, Lipids Health Dis, 20, 60, 10.1186/s12944-021-01490-0 · DOI
  12. Kasahara, 2013, High level of plasma remnant-like particle cholesterol may predispose to development of hypertension in normotensive subjects, Am J Hypertens, 26, 793, 10.1093/ajh/hpt011 · DOI
  13. Chen, 2022, High remnant cholesterol level potentiates the development of hypertension, Front Endocrinol, 13, 830347, 10.3389/fendo.2022.830347 · DOI · Paper page
  14. Wang, 2022, The association of remnant cholesterol (RC) and interaction between RC and diabetes on the subsequent risk of hypertension, Front Endocrinol, 13, 951635, 10.3389/fendo.2022.951635 · DOI
  15. Xu, 2021, Change in postprandial level of remnant cholesterol after a daily breakfast in Chinese patients with hypertension, Front Cardiovasc Med, 8, 685385, 10.3389/fcvm.2021.685385 · DOI
  16. Zheng, 2022, Hypertension, remnant cholesterol and cardiovascular disease: evidence from the China health and retirement longitudinal study, J Hypertens, 40, 2292, 10.1097/HJH.0000000000003259 · DOI
  17. Zhang, 2020, Strategy of blood pressure intervention in the elderly hypertensive patients (STEP): rational, design, and baseline characteristics for the main trial, Contemp Clin Trials, 89, 105913, 10.1016/j.cct.2019.105913 · DOI
  18. Ma, 2006, Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease, J Am Soc Nephrol, 17, 2937, 10.1681/ASN.2006040368 · DOI
  19. D’Agostino, 2008, General cardiovascular risk profile for use in primary care, Circulation, 117, 743, 10.1161/CIRCULATIONAHA.107.699579 · DOI · Paper page
  20. Castañer, 2020, Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease, J Am Coll Cardiol, 76, 2712, 10.1016/j.jacc.2020.10.008 · DOI · Paper page
  21. Elshazly, 2020, Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease, Eur J Prev Cardiol, 27, 1091, 10.1177/2047487319887578 · DOI · Paper page
  22. Liu, 2022, Association between remnant cholesterol and arterial stiffness in a Chinese community-based population: a cross-sectional study, Front Cardiovasc Med, 9, 993097, 10.3389/fcvm.2022.993097 · DOI
  23. Charakida, 2010, Assessment of atherosclerosis: the role of flow-mediated dilatation, Eur Heart J, 31, 2854, 10.1093/eurheartj/ehq340 · DOI
  24. Dinh, 2014, Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension, BioMed Res Int, 2014, 406960, 10.1155/2014/406960 · DOI
  25. Ohnishi, 2002, Relationship between insulin-resistance and remnant-like particle cholesterol, Atherosclerosis, 164, 167, 10.1016/S0021-9150(02)00057-6 · DOI
  26. Inoue, 2002, Possible relationship between insulin resistance and remnant-like lipoprotein particles in coronary endothelial dysfunction, Clin Cardiol, 25, 532, 10.1002/clc.4960251110 · DOI
  27. Huang, 2022, Emerging evidence of pathological roles of very-low-density lipoprotein (VLDL), Int J Mol Sci, 23, 4300, 10.3390/ijms23084300 · DOI
  28. Tsai, 2017, Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production, J Endocrinol, 232, R115, 10.1530/JOE-16-0237 · DOI
  29. The SPRINT Research Group, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939 · DOI · Paper page
  30. Phillips, 2018, Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension, J Am Coll Cardiol, 71, 1601, 10.1016/j.jacc.2018.01.074 · DOI · Paper page
  31. Bress, 2021, Patient selection for intensive blood pressure management based on benefit and adverse events, J Am Coll Cardiol, 77, 1977, 10.1016/j.jacc.2021.02.058 · DOI
  32. Attar, 2019, Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: a secondary analysis of the SPRINT trial, Eur J Prev Cardiol, 26, 238, 10.1177/2047487318800741 · DOI
  33. Cheng, 2021, The U-shaped association of non-high-density lipoprotein cholesterol levels with all-cause and cardiovascular mortality among patients with hypertension, Front Cardiovasc Med, 8, 707701, 10.3389/fcvm.2021.707701 · DOI
  34. Johannesen, 2020, Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study, BMJ, 371, m4266, 10.1136/bmj.m4266 · DOI
  35. Nordestgaard, 2018, Advances in lipid-lowering therapy through gene-silencing technologies, Nat Rev Cardiol, 15, 261, 10.1038/nrcardio.2018.3 · DOI
  36. Varbo, 2021, Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction, Eur Heart J, 42, 4833, 10.1093/eurheartj/ehab293 · DOI
  37. Wadström, 2023, Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality, Eur Heart J, 44, 1432, 10.1093/eurheartj/ehac822 · DOI

Cited by

Sorted by citations

See all 12

Metadata

Authors
Yang, R., Zhang, J., Yu, X., Yang, G., & Cai, J.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Shanxi Medical University (CN)
  • Department of Cardiology, Benxi Railway Hospital , No. 25 Yingchun Street, Pingshan District, Benxi, Liaoning Province 117000 , China
  • Chinese People's Armed Police Force (CN)
Corresponding author
Cai, Jun
Venue
European Journal of Preventive Cardiology
Published
2024-01-03
Volume
31
Issue
8
Pages
997-1004
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W4390531708
Cited by
12
References
0
Citations by year
2026: 5 · 2025: 5 · 2024: 2
FWCI
3.61
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Preventive Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • CAMS Innovation Fund for Medical Sciences (2021-I2M-1-007)
  • National Natural Science Foundation of China (81825002)
  • Beijing Outstanding Young Scientist Program (BJJWZYJH01201910023029)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
Keywords
remnant cholesterol, intensive blood pressure lowering, systolic blood pressure, hypertension, older adults, cardiovascular outcomes, all-cause mortality, treatment effect heterogeneity, STEP trial
MeSH terms
Age Factors, Aged, Aged, 80 and over, Antihypertensive Agents, Blood Pressure, Cholesterol, Female, Humans, Hypertension, Male, Risk Factors, Time Factors, Biomarkers, Treatment Outcome, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review